Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24

Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.

Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030

Intent to start at least 5 innovative Phase 3 vaccine programs by 2025

GSK receives USFDA Fast Track designation for investigational vaccine against gonorrhoea

Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing

Wacker Biotech partners with Caeregen Therapeutics on regenerative treatment for vision loss

As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands

Natural Capsules announces strategic investment by Somerset Indus Capital Partners

Fortis Healthcare to divest its Vadapalani, Chennai Hospital business operations to Kauvery Group of Hospitals

Polyplastics announces commercial availability of DURACON POM PM Series for medical industry

The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.

Augnito to launch ambient technology for clinical documentation

Augnito’s AI comprehends all English accents with 99% accuracy

Alkem Laboratories launches awareness initiative "Stop Sneeze to Wheeze"

Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis

Nanoform and Celanese demonstrate enhanced drug delivery through smaller implants

The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.